Key facts
- This page summarizes Stuart Diamond's Form 4 filing for bioAffinity Technologies, Inc. (BIAF).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 06 Jul 2023, 16:15.
Stuart Diamond - 01 Jan 2023 Form 4 Insider Report for bioAffinity Technologies, Inc. (BIAF)
- Reporting relationship
- Director
- Issuer ticker
- BIAF
- Reported as of
- 01 Jan 2023
- Net transaction value
- +$56,255
- SEC form
- 4
- Accepted by SEC
- 06 Jul 2023, 16:15:25 UTC
- Prior SEC filing
- 02 Dec 2022
- Next SEC filing
- 24 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Stuart Diamond
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Stuart Diamond filed Form 4 for bioAffinity Technologies, Inc. (BIAF) on 06 Jul 2023.
Change
- Previous filing in this sequence was filed on 02 Dec 2022.
- Current net transaction value: +$56,255.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BIAF
transaction
Common Stock
Award
- Transaction value
- $18,758
- Shares
- +8,227
- Change %
- +202%
- Price
- $2.28
- Shares after
- 12,308
- Date
- 01 Jan 2023
- Ownership
- Direct
- Footnotes
- F1
BIAF
transaction
Common Stock
Award
- Transaction value
- $18,749
- Shares
- +9,920
- Change %
- +81%
- Price
- $1.89
- Shares after
- 22,228
- Date
- 15 Apr 2023
- Ownership
- Direct
- Footnotes
- F2
BIAF
transaction
Common Stock
Award
- Transaction value
- $18,748
- Shares
- +10,245
- Change %
- +46%
- Price
- $1.83
- Shares after
- 32,473
- Date
- 01 Jul 2023
- Ownership
- Direct
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents a grant from bioAffinity Technologies, Inc. (the "Issuer") to Mr. Diamond of 8,227 restricted shares of common stock, par value $0.007 (the "Common Stock"), on January 1, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year.
Footnote F2
Represents a grant from the Issuer to Mr. Diamond of 9,920 restricted shares of Common Stock on April 15, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest one-third on the date of grant, one-third on May 1, 2023 and the remaining shares on June 1, 2023, provided Mr. Diamond continues to serve as a director, and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year.
Footnote F3
Represents a grant from the Issuer to Mr. Diamond of 10,245 restricted shares of Common Stock, on July 1, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year.